during the swiftly evolving area of cancer therapeutics, being familiar with the intricate mechanisms of Antibody-Drug Conjugates (ADCs) is vital for creating effective solutions. Probably the most promising approaches is the use of in vitro bystander outcome assays, which Perform a pivotal job in improving therapeutic efficacy. These assays, provi